INTRODUCTION
Tobacco smoking continues to be a major health problem, with rates of smoking remaining steady at approximately 20% of the adult American population (CDC, 2010) . Nicotine is the primary addictive chemical in tobacco smoke and exerts its initial reinforcing effects through the mesolimbic dopamine (DA) system(Di Chiara and Imperato, 1988) . Specifically, nicotine releases DA by binding to a 4 b 2 -nicotinic acetylcholine receptors located on the mesolimbic DA neurons in the ventral tegmental area, resulting in neuronal firing and DA release in the nucleus accumbens and dorsal caudate (Imperato et al, 1986) . In preclinical microdialysis studies, acute doses of nicotine consistently increased DA by up to 200% from baseline (Brazell et al, 1990; Dewey et al, 1999; Di Chiara and Imperato, 1988; Gerasimov et al, 2000; Imperato et al, 1986) .
Positron emission tomography (PET) imaging can also be used to examine drug-induced DA release. Drugs, such as amphetamine, increase synaptic DA, which competes with the radiotracer to bind at the DA receptor. An increase in DA results in a decrease in radiotracer binding compared with baseline. In this study, we measure this change in binding potential (BP ND ), which is an indirect measure of the change in synaptic DA. Amphetamine administration results in a reliable and robust increase in extracellular DA (B1000% increase from baseline in microdialysis studies) (Di Chiara and Imperato, 1988) and has been widely used in brain imaging studies to probe DA function (Laruelle, 2000; Slifstein et al, 2010) . Attempts have also been made to measure nicotine-and tobacco smoking-induced DA release, but with inconsistent results.
In preclinical [ 11 C]raclopride studies nicotine challenges (ranging from 0.01 to 0.06 mg/kg, intravenously) resulted in 5-12% reductions in BP ND in the caudate and putamen of monkeys (Dewey et al, 1999; Marenco et al, 2004) . Similarly, a nicotine (0.05-0.5 mg/kg) challenge in pigs resulted in a 10% decrease in ventral striatal BP ND (Cumming et al, 2003) . Although an acute nicotine injection did not change [ 11 C]raclopride BP ND in awake monkeys, BP ND was reduced in anesthetized monkeys (Tsukada et al, 2002) , suggesting that anesthetics routinely used in non-human primate imaging may confound data interpretation. In humans, cigarette smoking consistently reduced [
11 C]raclopride BP ND by B8% (Brody et al, 2006 (Brody et al, , 2009a (Brody et al, , 2010 and up to 10% (Scott et al, 2007) in the ventral striatum in acutely abstinent tobacco smokers, but also see Barrett et al (2004) . Note that nicotine alone may not be responsible for smoking-induced DA release. There are approximately 4000 chemicals in tobacco smoke, and one or more of these compounds may act alone or in concert with nicotine and the behavioral aspects of smoking to produce reinforcing and dopaminergic effects. For example, harman, an MAO inhibitor, may contribute to the reinforcing effects of cigarette smoking via a dopaminergic mechanism (Talhout et al, 2007; Villegier et al, 2007) . Modest (B7%) reductions in [ 11 C]raclopride BP ND were found using nicotine gum (Takahashi et al, 2007) but not nicotine nasal spray (Montgomery et al, 2007) (Narendran et al, 2006; Willeit et al, 2006 Willeit et al, , 2008 . Improved sensitivity of [ Shotbolt et al, 2012) . Our objective was to take advantage of the sensitivity of [
11 C]PHNO to measure the small DA signal induced by nicotine. In addition, [ 11 C]PHNO has a higher affinity for D3 vs D2 DA receptors, which allows for regional interpretation of D3 and D2 receptors (Girgis et al, 2011) . Specifically, in human, binding in the dorsal striatum is primarily D2, binding in the substantia nigra is primarily D3, and binding in the globus pallidus is mixed with approximately 65% D3 vs D2 DA receptors (Tziortzi et al, 2011) . This provides an additional advantage over [ 11 C]raclopride, which is constrained to the D2 DA receptor-rich areas in the striatum. In this study, we measured nicotineand amphetamine-induced DA release in non-human primates with [ 
MATERIALS AND METHODS

Animals and Study Plan
Seven rhesus monkeys were included in the study (6 males, 1 female, body weight ¼ 10.6 ± 3.3 kg, age ¼ 6.7 ± 2.2 years). All experiments were conducted in accordance with the Yale University Institutional Animal Care and Use Committee guidelines. To avoid potential carryover effects of the radiotracer from one injection to the next, only one scan was performed per day and per animal. For the [
11 C]PHNO study, all seven animals underwent one baseline scan; then, three animals underwent a retest scan, six animals underwent one postnicotine scan, and four animals underwent a postamphetamine scan. Five animals were included in the [ 11 C]raclopride study: all five animals underwent one baseline scan and one postnicotine scan, and four animals underwent one postamphetamine scan (Table 1) .
Radiochemistry
[ 11 C]PHNO was prepared by N-acylation of the norpropyl precursor with [ 11 C]propionyl chloride followed by reduction of the resulting amide with lithium aluminum hydride and purification by reverse-phase HPLC, in a modified literature procedure similar to that used for the preparation of [ 11 C]NPA (Brown et al, 1997; Hwang et al, 2000; Wilson et al, 2005) as described previously (Gallezot et al, 2012) . The purified [ 11 C]PHNO product was formulated in 1 ml of USP absolute ethanol and 10 ml of USP sterile saline. Filtration of the ethanolic saline solution through a 0.22 mm Millipore membrane filter produced a sterile apyrogenic 
PET Imaging
Animals were initially anesthetized with ketamine hydrochloride (10 mg/kg, intramuscularly), transported to the PET facility, intubated, and maintained on oxygen and 1.5-4.0% isoflurane throughout the study. A 2-h interval was allowed between ketamine administration and injection of the radiotracer or drugs. Vital signs including respiration rate, blood pressure, heart rate, and temperature were monitored continuously and recorded every 15 min, and temperature was kept constant at 37 1C with heated water blankets. Arterial blood sampling was performed using a vascular access port, that is, a thin catheter leading from the femoral artery to a port implanted subcutaneously in the area of the hip, upper thigh, or dorsum, during a previous surgery. PET scans were performed on the Focus 220 PET scanner (Siemens/CTI, Knoxville, TN, USA), which has an intrinsic resolution of 1.4 mm at the center of the field of view. A transmission scan was acquired for image reconstruction.
Amphetamine and nicotine were obtained from Sigma Aldrich (St Louis, MO, USA). For amphetamine studies (n ¼ 8), 0.4 mg/kg of amphetamine salt was administered as a 1-min bolus 5.0 ± 0.1 min before tracer injection. For nicotine studies (n ¼ 11), 0.18±0.01 mg/kg of nicotine was administered using a bolus-plus-infusion protocol started 21 ± 10 min before tracer injection. The bolus phase lasted 5 min (0.10 ± 0.01 mg/kg) and the infusion 32 ± 7 min (0.08±0.01 mg/kg). Arterial blood samples were obtained for analysis of nicotine and cotinine or amphetamine at 2, 5, 15, 25 and 50 min after drug injection.
[ Dynamic scan data were binned into a sequence of 33 frames (6 Â 30 s; 3 Â 1 min; 2 Â 2 min; 22 Â 5 min), and each frame was reconstructed with the appropriate corrections (attenuation, normalization, scatter, randoms, and deadtime), using a FORE/FBP algorithm and a Shepp filter with a cutoff frequency of 0.15 times the sampling frequency (reconstructed image resolution approximately 3.2 mm).
Arterial Input Function Measurement for [ 
MR Imaging
MR images were acquired for each rhesus monkey on a Siemens 3.0 T Trio scanner, using an extremity coil. T1-weighted images were acquired in the coronal plane with a spin echo sequence (TE ¼ 3.34, TR ¼ 2530, flip angle ¼ 71, section thickness ¼ 0.50 mm, field of view ¼ 140 mm, image matrix ¼ 256 Â 256 Â 176 pixels, matrix size ¼ 0.547 Â 0.547 Â 0.500 mm 3 ). Non-brain tissue was removed and the image cropped to 176 Â 176 Â 176 pixels using MEDx software (Medical Numerics, Germantown, MD) before coregistration with PET images.
Region of Interest Delineation
An existing region of interest (ROI) map defined on a template brain (a representative MR image of a brain, from an animal not included in the study) was utilized. The following, a priori defined, ROIs were examined: cerebellum (5.9 cm C]PHNO has moderate binding in the thalamus (BP ND B0.3), this region was not part of our primary hypothesis and was excluded a priori to avoid reducing statistical power (due to multiple comparisons) in higher binding regions. The regions were drawn on coronal slices on the template MR image. In particular, the substantia nigra was drawn on seven consecutive slices in the midbrain with location and shape of the ROI based on a histological atlas (Paxinos et al, 2000) . The cerebellum ROI includes both gray and white matter tissues. A nonlinear transformation was used (bioimagesuite program; version 2.5; http:// www.bioimagesuite.org/) to transfer the ROI template to the MR image of each subject. Then, the MR and PET images of each monkey were coregistered using a rigid body registration using an automatically selected PET sum image (Sandiego et al, 2013) . ]raclopride BP ND were quantified using the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) using the cerebellum time-activity curve (TAC) as input data. The SRTM operational equation is:
Kinetic Modeling
where R 1 is the relative influx rate in the target region, k 2 and k 0 2 are the efflux rates from the target and reference regions, respectively, and BP ND is equal to R 1 k 0 2 =k 2 À 1. (Innis et al, 2007) were quantified using the multilinear analysis MA1 (Ichise et al, 2002) using the arterial input function, and the cerebellum as reference region to estimate the non-displaceable volume of distribution (V ND ). MA1 is based on the graphical analysis (Logan et al, 1990) . As arterial input functions were not available for all [ 11 C]PHNO studies, binding potentials BP ND were also estimated using two reference region methods: SRTM and MRTMS, both using the cerebellum TAC as input data. This second reference method is a simplification of the multilinear methods MRTM and MRTM2 (Ichise et al, 2008; Ichise et al, 2002) . MRTMS differs from MRTM and MRTM2 in that it drops a term on the right-hand side of the equation directly proportional to the reference tissue concentration. This approach is based on the same hypotheses as the simple form of reference region graphical analysis (Gunn et al, 2002; Logan et al, 1996 ; see equation 7). The MRTMS, operational equation is:
where C T and C Ref represent the target ROI and the cerebellum TACs, respectively. The time t* after which the underlying graphical analysis plot is considered linear was set to 20 min for MA1 and 40 min for MRTMS.
Statistical Analysis
Test-retest variability (TRV) of [ 11 C]PHNO BP ND was assessed by computing the mean and standard deviation of
Linear mixed models were used to examine changes in BP ND levels across drug and region. Separate models were developed for each radiotracer with three regions (caudate, putamen, nucleus accumbens) and five regions (caudate, putamen, nucleus accumbens, globas pallidus, substantia nigra) included in the [ 11 C]raclopride and [
11 C]PHNO models, respectively. In these models, both drug (baseline, nicotine, amphetamine) and region were modeled as within-subjects factors. Within-subject correlations were accounted for with random subject effects and by fitting the best variance-covariance structure to the data according to the Bayesian Information Criterion. For the [
11 C]PHNO model, separate variance and covariance parameters were estimated within each region, based on regional heterogeneity. Owing to the limited size of the current sample, we report unadjusted p-values (po0.05). Spearman's correlations were used to examine relationships between changes in BP ND and plasma levels of nicotine and amphetamine. Statistical calculations were performed using SAS, version 9.3 (SAS, Cary, NC).
Effect size was computed as the absolute value of the mean difference of the BP ND , before and after drug (either nicotine or amphetamine), divided by the standard deviation of the differences. Statistical power computations were performed using G*Power 3 (version 3.1.6), using a power (b) of 0.8 and an error probability (a) of 0.05, and a onetailed hypothesis, as in a previous study with nicotine and [
11 C]raclopride (Marenco et al, 2004) . Table 2 . The test and retest BP ND estimates were not significantly different in any region (paired Student's t-test, the smallest p-value was 0.12, in the substantia nigra). The TRV of BP ND , estimated as the standard deviation of the difference in BP ND , ranged from 6% in the nucleus accumbens to 17% in the caudate and substantia nigra.
Plasma Levels of Nicotine and Amphetamine
Amphetamine levels (ng/ml) in the blood peaked rapidly at 391 ± 26 (2 min), and then progressively declined as follows: 192±28 (5 min), 133±23 (15 min), 112±19 (25 min), and 94±19 (50 min). Areas under the curve (until 50 min) for all amphetamine studies were 6305 þ 834 ng/ml Á min. Nicotine levels (ng/ml) in the blood were as follows: 127±47 (2 min), 176±48 (5 min), 64±15 (15 min), 65±10 (25 min), and 31 ± 6 (50 min) consistent with a bolus plus constant infusion administration. Areas under the curve (until 50 min) for all nicotine studies were 4044 þ 737 ng/ml Á min. Levels of cotinine (ng/ml), the major metabolite of nicotine, in the blood were as follows: 0.7 ± 1.2 (2 min), 21 ± 19 (5 min), 57±24 (15 min), 77±23 (25 min), and 104±25 (50 min).
Nicotine-and Amphetamine-Induced BP ND Changes with [
C]PHNO
The effects of the nicotine and amphetamine on [ 11 C]PHNO BP ND are presented in Table 3 and Figure 1 . There was a GP 6.5 ± 0.9 6 ± 14 S. nigra 4.3 ± 1.6 2 ± 17
Abbreviations: GP, globus pallidus; N. acc, nucleus accumbens; S. nigra, substantia nigra.
significant main effect of drug (F(2,8)X89, po0.0001). Post hoc tests indicate that amphetamine significantly reduced BP ND (po0.0001) in all regions ( À 29 ± 6 to À 64 ± 6%), and nicotine significantly reduced BP ND in the caudate ( À 7±8%, p ¼ 0.02), the nucleus accumbens ( À 10±7%, p ¼ 0.006), and the globus pallidus ( À 13 ± 15%, p ¼ 0.04) but not in the putamen (p ¼ 0.14) or the substantia nigra (p ¼ 0.68). The effect size was lowest in the substantia nigra (0.17 for nicotine and 1.9 for amphetamine), and highest in the caudate for amphetamine (11.0) and in the nucleus accumbens for nicotine (1.20).
C]raclopride
The effects of nicotine and amphetamine on [ 11 C]raclopride BP ND are presented in Table 4 and Figure 1 . In the caudate, putamen, and nucleus accumbens, where there is measurable [
11 C]raclopride BP ND , the main effect of drug was significant (F(2,29)X14.6, po0.0001). Post hoc tests indicate that amphetamine significantly reduced BP ND (po0.01) in all three regions ( À 33±7 to À 35±15%), whereas nicotine did not significantly reduce BP ND in any region (2 ± 13 to17 ± 16%). There was a significant increase in BP ND in the nucleus accumbens (po0.01). This is partially because, in one monkey, nicotine resulted in increased BP ND in all regions (25% in the putamen to 38% in the nucleus accumbens) and this was not consistent with the other four animals across regions ( À 2±9% in the putamen to 12 ± 13% in the nucleus accumbens). Owing to the variable and unexpected direction of the change of BP ND with nicotine, the effect size was only computed for amphetamine studies. The effect size was 2.0 in the caudate and putamen and 4.5 in the nucleus accumbens. PHNO -Nicotine Nicotine produced small (6-10%) but significant reductions in striatal BP ND with [ (Brody et al, 2010 (Brody et al, , 2009a Scott et al, 2007) and are also consistent with the preclinical literature reporting small but significant (5-10%) reductions in [ 11 C]raclopride BP ND by intravenous nicotine (0.06-0.5 mg/kg, intravenously) (Cumming et al, 2003; Marenco et al, 2004) . In our hands, [ 11 C]PHNO TRV was higher at 7 þ 17% in the caudate and 2 þ 10% in the putamen based on data from three monkeys. This suggests that a 6-10% reduction in [
11 C]PHNO BP ND by nicotine is not greater than the variability we find in the current study within baseline [ 11 C]PHNO scans. A limitation is that the current study may have been underpowered to detect a larger effect in the striatum and studies involving human subjects will have larger sample sizes. In fact, the effect sizes in the nicotine experiments with [ 11 C]PHNO in the current study were similar (putamen) or higher (other basal ganglia ROIs) than the effect size reported previously (Marenco et al, 2004) (Lammertsma and Hume, 1996) and the simple form of the noninvasive graphical analysis (Gunn et al, 2002; Logan et al, 1996 ; equation 7) can be used to quantify [ 11 C]PHNO BP ND without arterial blood sampling (Ginovart et al, 2007b) . However, in the current study, in rhesus monkeys SRTM tended to underestimate [
11 C]PHNO BP ND , especially in regions with high BP ND values (eg, in the pallidum SRTM BP ND values were 15±4% lower than with MA1). SRTM has not previously been extensively compared with methods using arterial blood sampling in rhesus monkeys. This underestimation may be due the higher BP ND values observed in rhesus monkeys (7.0±0.6 in the pallidum) than in humans (mean pallidum BP ND values were within the 3-4 range depending on the method (Ginovart et al, 2007a) . MRTMS, which is based on the same hypotheses as the simple form of the noninvasive graphical analysis, but reduces the noise-induced bias seen in the graphical analyses like the MRTM and MRTM2 methods, provided [ 11 C]PHNO BP ND estimates that were better correlated with BP ND values obtained using arterial blood sampling. MRTMS is similar to MRTM, but one less parameter needs to be estimated in MRTMS, which can help reduce the variability of BP ND estimates. Conversely, MRTMS is applicable to fewer tracers than MRTM or MRTM2, in the same manner that the simpler form of the noninvasive graphical analysis (Gunn et al, 2002; Logan et al, 1996 ; equation 7) is applicable in fewer cases than the three-parameter form (Ichise et al, 1996; Logan et al, 1996; equation 6) .
The injected mass of [ 11 C]PHNO used in this study (0.08 mg/kg) is below the tracer dose limit for D 2 receptors but not for D 3 receptors. In humans, the recommended dose of [ 11 C]PHNO is 0.029 mg/kg or lower, to reduce the frequency of side effects (Mizrahi et al, 2010) . The true tracer dose of [ 11 C]PHNO at D 3 receptors may be lower still. In anesthetized rhesus monkeys, the tracer dose limit may be higher than in humans as the uptake of [
11 C]PHNO is lower in the cerebellum of anesthetized rhesus monkeys than in humans. The average SUV at 60-120 min after injection in the cerebellum measured in our laboratory was 0.36±0.06 (n ¼ 34 baseline scans) and 0.63±0.10 (n ¼ 48 baseline scans) in rhesus monkeys and humans, respectively. We estimated that the tracer dose in rhesus monkeys is 0.01-0.02 mg/kg (for 5% occupancy) in a previous study (Gallezot et al, 2012) . Based on that study, the selfoccupancy of [ C]raclopride owing to the more complicated synthesis. We decided to use a higher than tracer dose as a trade-off to reduce the noise in PET images.
The dose of nicotine (0.18 mg/kg over 30 min) used in this study was based on earlier work by Domino and Tsukada (2009) that reported a 300% increase in striatal DA above baseline measured with microdialysis in awake monkeys. The increase was sustained for over 2 h, suggesting that we did not miss a transient change in DA. It is possible that increases in extrasynaptic DA measured by microdialysis do not directly reflect changes in synaptic DA levels and the paradigm chosen may not have been optimal to measure changes in synaptic levels of DA. The aim of the study was to elicit maximal DA release to determine if it could be reliably measured with [ 11 C]raclopride or [
11 C]PHNO. Earlier preclinical studies using bolus nicotine administration (Cumming et al, 2003; Dewey et al, 1999; Marenco et al, 2004) , which more closely resemble human smoking, did not find larger changes in BP ND than ours. Those papers reported changes on the order of 5-10%, similar to our findings.
Even though an initial human smoking study reported relatively large changes in BP ND (Brody et al, 2004) , followup studies by the same group concluded that smoking a cigarette causes an approximate 8% reduction in BP ND . These findings are generally consistent with the preclinical studies reviewed above. We note one important difference between the human and animal studies is that the humans are nicotine-dependent. Interestingly, microdialysis studies suggest slightly greater nicotine-induced DA release in nicotine pre-treated vs saline-treated animals (Marshall et al, 1997; Shim et al, 2001 ). Thus, it is possible that smoking-induced DA release is somewhat greater in nicotine-dependent subjects compared with the preclinical studies. We are currently developing and evaluating alternative methods for measuring smoking-induced DA release in chronic human tobacco smokers Sullivan et al, 2013) . These methods are designed to detect brief DA changes that may be localized to subregions of the striatum.
In addition to finding significant reductions in striatal BP ND with nicotine and [ (Fuchs et al, 2005; Hauber and Fuchs, 2000) . This suggests a role for the globus pallidus in appetitive behavior, which may include drug abuse. Although amphetamine administration (0.42 mg/kg, per os) to humans did not significantly reduce [ 11 C]PHNO BP ND in the globus pallidus (6.5%), we found a significant reduction (29%) with amphetamine (0.4 mg/kg, intravenously) in anesthetized non-human primates. The difference in results may be due to the differences in the route of administration or to anesthesia.
[ 11 C]PHNO has been shown to have greater sensitivity over [
11 C]raclopride to amphetamine-induced striatal DA release in healthy human (Shotbolt et al, 2012) and in cat brain 11 C]PHNO can be used to measure binding in D 3 -rich regions, such as the globus pallidus and substantia nigra. As DA has higher affinity for D 3 receptors, a given amount of released DA would produce a larger change in the globus pallidus than in the caudate or putamen. This may be a contributing factor to our ability to detect a significant nicotine-induced change in the pallidum. As for PHNO in the substantia nigra, which is effectively all D 3 , this region's small size in combination with a relatively less robust effect of nicotine vs amphetamine on DA release, makes reliable detection of changes more difficult. The two other regions with the highest ratio of D 3 to D 2 receptors (pallidum, nucleus accumbens) are also intrinsically small and suffer from partial volume effects, with both spill-out of the signal outside of the region and spill in for neighboring D2-rich regions. This would reduce the benefits of being able to observe both D 2 and D 3 receptors with [
11 C]PHNO. In future studies, improvement in specific activities or improvement in reconstruction algorithms and noise reduction techniques may help to obtain higher resolution images. In human studies, the relative size of brain ROIs compared with the scanner resolution may be more favorable, especially since with the filtering included in the FBP algorithm in the current study, the resolution of the images (about 3.2 mm) is not much higher than that of the best dedicated brain scanners for human studies.
In the current study, we detected significant striatal (caudate and nucleus accumbens) DA release induced by nicotine with [ 
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